Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Vercauteren, Jurgen ^a   Beheydt, Gertjan ^a   Prosperi, Mattia ^b   Libin, Pieter ^a   Imbrechts, Stijn ^a   Camacho, Ricardo ^c,n   Clotet, Bonaventura ^d   De Luca, Andrea ^e   Grossman, Zehava ^f,o   Kaiser, Rolf ^g   Sönnerborg, Anders ^h   Torti, Carlo ⁱ   Van Wijngaerden, Eric ^j   Schmit, Jean Claude ^k   Zazzi, Maurizio ^l   Geretti, Anna Maria ^m   Vandamme, Anne Mieke ^a   Van Laethem, Kristel ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Centro Hospitalar de Lisboa Ocidental   (Portugal)

^d IrsiCaixa Foundation   (Spain)

^e CATHOLIC UNIVERSITY   (Italy)

^f SHEBA MEDICAL CENTER   (Israel)

^g UNIVERSITY OF COLOGNE   (Germany)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^l UNIVERSITY OF SIENA   (Italy)

^m ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁿ INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^o TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; DATA BASE; FEMALE; GENETIC ALGORITHM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; REGA 8 ALGORITHM; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; WILCOXON SIGNED RANKS TEST;

ADULT; ALGORITHMS; ANTI-HIV AGENTS; DATABASES AS TOPIC; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84876273802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061436     Document Type: Article

References (24)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, et al. (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352: 1725-30.
2. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: the journal of the American Medical Association 304: 321-33.
3. Wilson LE, Gallant JE, (2009) HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 48: 214-21.
4. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, et al. (2008) The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 5: 12.
5. Vercauteren J, Vandamme AM, (2006) Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral research 71: 335-42.
6. Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, et al. (2007) The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (London, England) 21: 2033-42.
7. Helm M, Walter H, Ehret R, Schmit JC, Kurowski M, et al. (2007) Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study. European journal of medical research 12: 231-42.
8. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, De Luca A, Palmisano L, et al. (2011) European Recommendations for the Clinical Use of HIV Drug Resistance Testing: 2011 Update. AIDS reviews 13: 77-108.
9. De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, et al. (2011) Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score. Antiviral therapy 16: 489-97.
10. Prosperi MCF, Altmann A, Rosen-Zvi M, Aharoni E, Borgulya G, et al. (2009) Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Antiviral therapy 14: 433-42.
11. De Luca A, Perno CF, (2003) Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing. Current opinion in infectious diseases 16: 573-80.
12. De Luca A, Cozzi-Lepri A, Perno CF, Balotta C, Di Giambenedetto S, et al. (2004) Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. Antiviral therapy 9: 743-52.
13. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, et al. (2009) Predictive value of HIV-1 genotypic resistance test interpretation algorithms. The Journal of infectious diseases 200: 453-63.
14. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, et al. (2002) A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antiviral therapy 7: 123-9.
15. Libin P, Deforche K, Van Laethem K, Camacho RJ, Vandamme Am (2007) RegaDB: An Open Source, Community-Driven HIV Data and Analysis Management Environment. In: Fifth European HIV Drug Resistance Workshop. Cascais, Portugal.
16. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics (Oxford, England) 21: 3797-800.
17. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 42: 1608-18.
18. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, et al. (2002) Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England) 16: 727-36.
19. Altmann A, Däumer M, Beerenwinkel N, Peres Y, Schülter E, et al. (2009) Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. The Journal of infectious diseases 199: 999-1006.
20. Frentz D, Boucher CAB, Assel M, De Luca A, Fabbiani M, et al. (2010) Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. PloS one 5: e11505.
21. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (London, England) 20: W13-23.
22. Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, et al. (2009) Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. The Journal of antimicrobial chemotherapy 64: 616-24.
23. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, et al. (1996) Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA: the journal of the American Medical Association 276: 118-25.
24. Staszewski S, Hill AM, Bartlett J, Eron JJ, Katlama C, et al. (1997) Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials. AIDS (London, England) 11: 477-83.